Mainolfi Nello 4

What happened

• Nello Mainolfi, Chief Executive Officer of Kymera Therapeutics (KYMR), exercised options and sold company stock on July 1, 2026. He exercised 80,000 shares at $2.08 per share (exercise cost $166,400) and completed open-market sales of 80,000 shares in multiple blocks, generating gross proceeds of approximately $9,223,528. A separate derivative entry shows 80,000 shares disposed at $0 (see footnotes/filing for detail). The shares underlying the option were fully vested and exercisable.
• These sales were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 (i.e., preplanned trades). This pattern—exercise of options followed by immediate market sales—is typically a liquidity/cashless exercise and is generally considered routine rather than a direct signal about company fundamentals.

Key details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (timely filing).
• Option exercise: 80,000 shares acquired at $2.08 each; total cost $166,400.
• Market sales (all on July 1, 2026): five blocks totaling 80,000 shares with weighted average prices and proceeds:
  • 1,883 shares at $112.80 — $212,411 (weighted avg; range $112.28–$113.27)
  • 6,626 shares at $113.98 — $755,204 (range $113.36–$114.23)
  • 24,105 shares at $114.96 — $2,771,002 (range $114.29–$115.27)
  • 44,050 shares at $115.69 — $5,096,070 (range $115.31–$116.23)
  • 3,336 shares at $116.56 — $388,841 (range $116.29–$116.63)
  • Total sales proceeds ≈ $9,223,528 (weighted averages reported; filing includes ranges per block).
• Additional derivative entry: 80,000 shares listed as exercised/converted and disposed at $0.00 (reported value $0) — see filing/footnote F8 (options fully vested). The filing does not provide detail in the summary about whether these represent net-share settlement or another administrative disposition; the Form 4 footnotes should be consulted for full detail.
• Footnotes of note:
  • F1: Trades effected under a Rule 10b5-1 plan dated March 24, 2026.
  • F2: A reported number in the filing includes 373 shares acquired under the company’s ESPP.
  • F3–F7: Weighted-average sale prices reported; each block includes the price range of the multiple executions.
  • F8: Shares underlying the option were fully vested and exercisable.
• Shares owned after the transactions: not specified in the data provided here (refer to the full Form 4 for post-transaction holdings).

Context

• For retail investors: this is primarily an executive exercising options at a low strike and selling shares under a prearranged 10b5-1 plan—commonly a liquidity move rather than an informative vote on company prospects.
• Transaction codes: M = option exercise/conversion; S = open market sale. When options are exercised and shares are immediately sold, it is often described as a cashless exercise or preplanned sale.